论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zeng B, Zhou M, Wu H, Xiong Z
Received 16 October 2017
Accepted for publication 16 December 2017
Published 12 March 2018 Volume 2018:11 Pages 1333—1343
DOI https://doi.org/10.2147/OTT.S154215
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 4
Editor who approved publication: Dr Ingrid Espinoza
Objectives: Ovarian cancer is one of the most lethal malignant tumors in women.
Secreted phosphoprotein 1 (SPP1) plays an important role in some cancer types.
Therefore, the role of SPP1 in ovarian cancer was determined and the potential
mechanism was elucidated.
Materials and methods: The expression of SPP1 in ovarian cancer was
determined by immunohistochemistry in ovarian cancer tissues and normal ovarian
tissues. Cellular proliferation, migration, and invasion were determined by
cell counting kit-8 assay, wound healing assay, and Matrigel invasion assay in
SKOV3 and A2780 cells. The protein expression of SPP1, integrin subunit β1
(Integrin β1), focal adhesion kinase (FAK), and phosphorylation protein
kinase B (p-AKT) was detected by Western blotting in SKOV3 cells after
silencing SPP1. The expression of SPP1 was determined in SKOV3 cells after
transfecting with miR-181a mimics or inhibitors. The growth of SKOV3 cells in
vivo was determined in a nude mouse model of ovarian cancer after silencing
SPP1.
Results: The expression of SPP1 was higher in epithelial
ovarian cancer tissues than in normal ovarian tissues. Silencing SPP1 decreased
the cell proliferation, migration, and invasion. Ectopic expression of SPP1
increased the cell proliferation, migration, and invasion. Silencing SPP1
prevented ovarian cancer growth in mice. Silencing SPP1 inhibited Integrin
β1/FAK/AKT pathway. In agreement, ectopically expressed SPP1 activated Integrin
β1/FAK/AKT pathway. Also, SPP1 was regulated by miR-181a.
Conclusion: SPP1 is a biomarker for the prognosis of ovarian
cancer. It is also oncogenic and a potential target for ovarian cancer therapy.
Keywords: ovarian cancer,
SPP1, Integrin β1, FAK, AKT, miR-181a
